Kimberly B. Koenig

1.3k total citations
15 papers, 855 citations indexed

About

Kimberly B. Koenig is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Kimberly B. Koenig has authored 15 papers receiving a total of 855 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Cancer Research and 4 papers in Molecular Biology. Recurrent topics in Kimberly B. Koenig's work include Breast Cancer Treatment Studies (7 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). Kimberly B. Koenig is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), HER2/EGFR in Cancer Research (5 papers) and Cancer Treatment and Pharmacology (3 papers). Kimberly B. Koenig collaborates with scholars based in United States, United Kingdom and Japan. Kimberly B. Koenig's co-authors include Gabriel N. Hortobágyi, James L. Murray, W. Fraser Symmans, Vicente Valero, Daniel J. Booser, Funda Meric‐Bernstam, Stacy L. Moulder, Thorunn Helgason, Razelle Kurzrock and Nuhad K. Ibrahim and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Kimberly B. Koenig

14 papers receiving 841 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberly B. Koenig United States	12	510	475	245	203	160	15	855
Ahmed Benhasouna United Kingdom	9	543 1.1×	452 1.0×	428 1.7×	139 0.7×	90 0.6×	10	937
Atsushi Shimomura Japan	21	513 1.0×	595 1.3×	439 1.8×	213 1.0×	88 0.6×	48	1.1k
Poh Yian Cheok Singapore	11	475 0.9×	397 0.8×	161 0.7×	206 1.0×	68 0.4×	13	742
Jamie R. Kutasovic Australia	15	348 0.7×	319 0.7×	304 1.2×	181 0.9×	58 0.4×	19	762
Barbara Dunne United Kingdom	12	482 0.9×	230 0.5×	536 2.2×	172 0.8×	241 1.5×	21	973
Anne‐Lise Børresen‐Dale Norway	15	446 0.9×	527 1.1×	822 3.4×	123 0.6×	210 1.3×	20	1.2k
JFR Robertson United Kingdom	12	435 0.9×	333 0.7×	327 1.3×	146 0.7×	138 0.9×	13	830
Sarab Lizard‐Nacol France	18	393 0.8×	331 0.7×	627 2.6×	261 1.3×	105 0.7×	33	1.1k
S. Johnston United Kingdom	9	433 0.8×	332 0.7×	341 1.4×	231 1.1×	84 0.5×	17	783
Rosalía Caballero Spain	14	639 1.3×	599 1.3×	454 1.9×	157 0.8×	178 1.1×	42	1.2k

Countries citing papers authored by Kimberly B. Koenig

Since Specialization

Citations

This map shows the geographic impact of Kimberly B. Koenig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly B. Koenig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly B. Koenig more than expected).

Fields of papers citing papers by Kimberly B. Koenig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly B. Koenig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly B. Koenig. The network helps show where Kimberly B. Koenig may publish in the future.

Co-authorship network of co-authors of Kimberly B. Koenig

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly B. Koenig. A scholar is included among the top collaborators of Kimberly B. Koenig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly B. Koenig. Kimberly B. Koenig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Yao, Shuyang, Filip Jankú, Kimberly B. Koenig, et al.. (2021). Phase 1 trial of ADI‐PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Medicine. 11(2). 340–347. 21 indexed citations

Lim, Bora, Juhee Song, Nuhad K. Ibrahim, et al.. (2020). A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. The Oncologist. 26(2). e230–e240. 5 indexed citations

Bashour, Sami I., Iman Doostan, Khandan Keyomarsi, et al.. (2017). Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. Journal of Cancer. 8(11). 2004–2009. 14 indexed citations

Mitri, Zahi, Rita Nanda, Kimberly Blackwell, et al.. (2016). TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clinical Cancer Research. 22(23). 5706–5712. 28 indexed citations

Basho, Reva, Michael Z. Gilcrease, Rashmi K. Murthy, et al.. (2016). Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. JAMA Oncology. 3(4). 509–509. 152 indexed citations

Arun, Banu, Yun Gong, Diane Liu, et al.. (2016). Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Research and Treatment. 158(1). 67–77. 16 indexed citations

Moulder, Stacy L., Thorunn Helgason, Filip Jankú, et al.. (2015). Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer. Annals of Oncology. 26(7). 1346–1352. 50 indexed citations

González-Angulo, Ana M., Xiudong Lei, James L. Murray, et al.. (2015). Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clinical Breast Cancer. 15(5). 325–331. 16 indexed citations

Basho, Reva, Filip Jankú, Thorunn Helgason, et al.. (2015). 1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC). European Journal of Cancer. 51. S289–S290.

10.

Heery, Christopher R., Nuhad K. Ibrahim, Philip M. Arlen, et al.. (2015). Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. JAMA Oncology. 1(8). 1087–1087. 82 indexed citations

11.

Agarwal, Rishi, Kimberly B. Koenig, Eric Rohren, & Vivek Subbiah. (2014). Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring aPIK3CAMutation. Journal of Breast Cancer. 17(3). 287–287. 6 indexed citations

12.

Yi, Min, Lei Huo, Kimberly B. Koenig, et al.. (2014). Which threshold for ER positivity? a retrospective study based on 9639 patients. Annals of Oncology. 25(5). 1004–1011. 172 indexed citations

13.

Esteva, Francisco J., Stacy Moulder, Ana M. González-Angulo, et al.. (2012). Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 71(1). 63–72. 27 indexed citations

14.

Iwamoto, Takayuki, Daniel J. Booser, Vicente Valero, et al.. (2012). Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry. Journal of Clinical Oncology. 30(7). 729–734. 212 indexed citations

15.

Moulder, Stacy L., John W. Moroney, Thorunn Helgason, et al.. (2011). Responses to Liposomal Doxorubicin, Bevacizumab, and Temsirolimus in Metaplastic Carcinoma of the Breast: Biologic Rationale and Implications for Stem-Cell Research in Breast Cancer. Journal of Clinical Oncology. 29(19). e572–e575. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact